B. Riley analyst Mayank Mamtani raised the firm’s price target on Journey Medical (DERM) to $12 from $9 and keeps a Buy rating on the shares following a transfer of coverage. The firm expects increased visibility into Emrosi’s early launch performance with the Q2 results in mid-August.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: